PIC/S PE 009-17 / Annex 1 Alignment

PIC/S is a co-operation scheme of pharmaceutical GMP inspectorates from 56 participating authorities (as of 2026). It maintains a harmonised GMP Guide that participating authorities adopt domestically — directly or by reference — and runs joint training, inspection support, audit programmes and mutual reliance arrangements. It is not a treaty body; participation is voluntary and binds the inspector authority, not the manufacturer directly.

Among PIC/S participants are FDA (joined 2011 for human medicines), MHRA, Health Canada, TGA Australia, MFDS Korea, HSA Singapore, Swissmedic, ANVISA Brazil, EMA (as observer-equivalent through EU NCAs), Japan PMDA/MHLW, and many EU national authorities. For globally distributed manufacturers, PIC/S alignment substantially reduces the divergence between GMP inspections across these jurisdictions.

• Annex 1 (Sterile Manufacturing) rewritten to align with EU GMP Annex 1 (2022). This is the dominant change in the revision.
• Annex 21 (Importation) added, mirroring EU GMP Annex 21 (effective Aug 2022).
• Various editorial and consistency updates to harmonise Part I/II/Annexes with EU GMP text.
• Effective date: 1 September 2023, harmonised with the EU Annex 1 applicability date (with limited transitional periods for specific elements such as biotechnology lyophiliser load-and-unload aseptic transfer).

1. Contamination Control Strategy (CCS) — a holistic, documented strategy across the entire facility integrating engineering, procedural and people controls. Required for every sterile manufacturing operation.
2. Quality Risk Management (QRM) — applied across facility design, equipment, processes, materials and personnel; aligned with ICH Q9(R1).
3. Premises and Equipment — clearer grading expectations (Grade A/B/C/D), pressure-differential expectations, smoke-study expectations, surface cleanliness and design-for-cleanability.
4. Barrier Technologies — strong preference for RABS and isolators; open-process aseptic operations require strong CCS justification.
5. Pre-Use Post-Sterilisation Integrity Testing (PUPSIT) — required for sterilising-grade filters with documented risk-based exceptions.
6. Aseptic Process Simulation (Media Fill) — clear expectations on frequency, batch size, intervention coverage and acceptance criteria (zero contaminated units in normal operation).
7. Environmental and Personnel Monitoring — risk-based and continuous, with trend analysis and excursion management.
8. Lyophilisation — explicit expectations on load/unload aseptic transfer, sterilisation and cleaning.
9. Sterilisation — process-specific expectations (moist heat, dry heat, ionising radiation, ethylene oxide, sterile filtration).
10. Form-Fill-Seal and Blow-Fill-Seal — operational expectations.
11. Personnel — gowning qualification, behaviour, training and intervention discipline.

Before PE 009-17, an FDA inspection (under cGMP for sterile drugs) and an EU inspection (under EU GMP Annex 1) often produced overlapping but not identical findings. With PE 009-17 in effect and FDA an active PIC/S participant, PIC/S inspectors (including FDA when conducting PIC/S-coordinated inspections) operate from a substantially aligned framework on sterile manufacturing.

• A single CCS document defensible against EU, FDA, MHRA, TGA, MFDS, HSA, Swissmedic and Health Canada inspections.
• A single aseptic process simulation programme defensible across jurisdictions.
• A single contamination-control investigation framework that produces findings recognised across PIC/S participants.
• Reduced inspection-rework and re-mediation cost for globally distributed sterile sites.

PIC/S PI 041 (Good Practices for Data Management and Integrity, finalised 2021) is the data-integrity companion to the GMP Guide. Its expectations — ALCOA+, audit trails, user-access control, dynamic-data preservation, paper-and-electronic-hybrid records, contract acceptor oversight — are referenced in PE 009-17 and applied across PIC/S inspections. Sites operating under PE 009-17 should treat PI 041 as the operative data-integrity expectation framework.

1. Confirm the site's CCS is in place, current, and integrates engineering, procedural and personnel controls across the facility — not just the cleanroom suites.
2. Cross-walk the CCS to the EU GMP Annex 1 (2022) requirements explicitly (Section 2 of Annex 1 is the CCS section). The same document satisfies both EU and PIC/S inspectors.
3. Verify aseptic process simulation programme against current expectations on frequency, batch size, intervention coverage and acceptance criteria.
4. PUPSIT — confirm implementation or document risk-based exceptions for legacy lines.
5. Smoke studies — current, video-archived, with intervention coverage; this is a frequent inspection focus.
6. Personnel gowning qualification — current, with intervention-specific reinforcement.
7. Data-integrity controls reviewed against PI 041; user-access reviews, audit-trail review SOPs and dynamic-data backup processes verified.
8. Self-inspection programme reorganised to cover the revised Annex 1 structure.

PIC/S alignment underpins (but does not replace) bilateral Mutual Recognition Agreements such as the EU-US MRA (which extends GMP-inspection reliance to most categories of human medicines). PIC/S participation gives the inspectorates the common framework that MRA-based reliance depends on. For manufacturers, an inspection by one MRA partner inspectorate against the PIC/S-aligned framework substantially reduces the need for separate inspections by the other.